HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
isbogrel
specific thromboxane A2 synthetase inhibitor
Also Known As:
7-phenyl-7-(3-pyridyl)-6-heptenoic acid; CV 4151; CV-4151; 6-Heptenoic acid, 7-phenyl-7-(3-pyridinyl)-, (E)-
Networked:
14
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Monounsaturated Fatty Acids: 676
isbogrel: 14
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridines: 88
isbogrel: 14
Related Diseases
1.
Ischemia
01/01/1991 - "
Morphological studies revealed that microthrombi were formed during ischemia, and CV-4151 mitigated the formation of microthrombi.
"
04/01/1986 - "
These findings indicate that TXA2 may contribute, at least partly, to the collagen-induced ECG changes and indicate that CV-4151 might be a favorable agent for the prevention of TXA2-mediated cardiac ischemia.
"
01/01/1994 - "
The sham group (n = 8) underwent the operation without ischemia-reperfusion; the control group (n = 8) with ischemia-reperfusion, and the CV-4151 group (n = 8) was pretreated with CV-4151 20 mg/kg. Skeletal muscle blood flow was measured by a hydrogen gas clearance method; the blood flow restored fully in the CV-4151 group, while it remained significantly low in the control group after 1 h of reperfusion (p < 0.05).
"
2.
Cardiovascular Diseases (Cardiovascular Disease)
12/01/1988 - "
These results indicate that CV-4151 may be suitable for clinical trials in cardiovascular diseases in which imbalance between thromboxane and prostacyclin may be involved in the pathogenesis.
"
3.
Thrombosis (Thrombus)
07/01/1995 - "
CV-4151 significantly inhibited photochemically induced MCA thrombosis by oral (1 and 10 mg/kg) and intravenous (1 mg/kg) administration.
"
07/01/1990 - "
The plasma level of 11-dehydro TXB2 increased significantly during thrombus formation, and CV-4151 (10 mg/kg) markedly inhibited this increase.
"
03/01/1995 - "
administration, CV-4151 and ozagrel inhibited femoral vein platelet-rich thrombosis caused by endothelial injury with ID50 values of 2.46 and 13.7 mg/kg, respectively.
"
07/01/1990 - "
CV-4151 (1,10 mg/kg, p.o.) and AA-2414 (10 mg/kg, p.o.) significantly inhibited thrombus formation.
"
03/01/1995 - "
CV-4151 and ozagrel given by i.v. injection showed therapeutic effects on the thrombosis with ED50 values of 0.026 and 0.066 mg/kg, respectively.
"
4.
Proteinuria
05/01/1991 - "
Any single specific inhibitor (CV-4151, a TXA2 synthetase inhibitor; AA-861, a 5-lipoxygenase inhibitor; or CV-3611, a radical scavenger) or a combination of two inhibitors showed no or only a slight antiproteinuric effect, but the combination of all three inhibitors significantly reduced PAN-induced proteinuria.
"
01/01/1991 - "
The proteinuria, however, could not be reduced by single administration of an inhibitor specific for thromboxane A2 synthase [(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (2, CV-4151)] or for 5-lipoxygenase [2-(12-hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-1,4-benzoquinone (1, AA-861)].
"
5.
Infarction (Infarctions)
07/01/1995 - "
CV-4151 (10 mg/kg, p.o.), furthermore, significantly reduced the infarct size and inhibited the increase in lactate content.
"
03/07/1989 - "
A thromboxane A2 synthetase inhibitor, CV-4151, and a lipoxygenase inhibitor, AA-861, greatly reduced the infarct size.
"
Related Drugs and Biologics
1.
Thromboxanes
2.
Epoprostenol (Prostacyclin)
3.
Thromboxane-A Synthase
4.
Thromboxane A2 (A2, Thromboxane)
5.
2,3,5- trimethyl- 6- (12- hydroxy- 5,10- dodecadiynyl)- 1,4- benzoquinone
6.
Lipoxygenase Inhibitors
7.
Ticlopidine (Ticlid)
8.
Ligases (Synthetase)
9.
Aspirin (Acetylsalicylic Acid)
10.
isbogrel